A molecule can fail for a very small reason. Not a grand theoretical reason. Not because the model lacks a cinematic vision of drug discovery. Sometimes the failure is an aromatic nitrogen that should carry hydrogen but does not. Sometimes it is a formal charge that disappears because the token vocabulary decided that “nitrogen” was enough detail. Chemistry, unfortunately, does not reward this sort of minimalism. ...
Glue sounds almost too gentle for Alzheimer’s disease. The usual business pitch for AI drug discovery prefers a louder vocabulary: acceleration, disruption, de-risking, platform advantage, and occasionally “revolution,” because apparently no investor memo can survive without one. This paper is more interesting when read against that noise. It does not show that AI has found an Alzheimer’s drug. It does not show that amyloid-β42 has been degraded in cells. It does not show brain delivery, toxicity control, animal efficacy, or clinical relevance. ...
Screening is not discovery. It is queue management with chemistry attached. A modern drug-discovery team can now look at chemical libraries with tens of billions of synthesizable molecules and ask a beautifully impractical question: which of these should we spend real money testing? Experimental high-throughput screening is expensive. Docking is cheaper, but still not cheap enough when the search space stops being “large” and starts behaving like a small galaxy. Co-folding and structure-aware models add another layer of sophistication, but they also add computational cost, data assumptions, and a healthy appetite for well-behaved structural regimes. ...
A lab does not slow down because nobody can generate molecules. That is the polite fiction. In many drug discovery workflows, candidate molecules can be generated in bulk. The slower part comes after generation: chemists inspect what the model proposes, explain what looks wrong or promising, and then someone has to translate that feedback into the model’s objective function. This “someone” is usually an AI engineer who understands the code but not necessarily the medicinal chemistry intuition. The chemist understands the target, the scaffold, and the quiet reasons a molecule feels suspicious. The model understands none of that unless the translation layer works. ...
A mid-sized biotech redesigned its AI-assisted discovery review from a generic research-assistant workflow into a specialist multi-agent process that improved strategic, regulatory, and translational decision quality.